氯胺酮的临床毒理学
本文综述氯胺酮的流行病学、毒性机制、药代动力学、临床特征、诊断与处理。检索OVID MEDLINE(1950年1月至2023年4月)和Web of Science(1900年至2023年4月),获得5,268条非重复引文,最终纳入185篇相关文献(病例报告、病例系列、药代动力学研究、药理学相关动物研究和综述)。氯胺酮急性不良反应包括意识受损、头晕、行为异常、幻觉、腹痛和呕吐;慢性使用可导致言语信息处理受损、膀胱炎和胆管病。急性中毒诊断基于病史、临床特征(呕吐、流涎或喉痉挛)及神经精神症状;慢性效应可通过内镜逆行胰胆管造影和膀胱镜确诊。处理以支持治疗为主,苯二氮䓬类药物推荐作为初始治疗以减少激越、过度神经肌肉活动和血压。
要点
- 急性氯胺酮中毒的诊断通常基于患者病史、临床特征(如呕吐、流涎或喉痉挛)以及神经精神症状。
- 苯二氮䓬类药物推荐作为初始治疗,用于减少激越、过度神经肌肉活动和血压升高。
- 氯胺酮急性中毒的处理以支持治疗为主,并对特定不良反应进行经验性处理。
- 慢性氯胺酮毒性可导致胆管病和膀胱炎,分别可通过内镜逆行胰胆管造影和膀胱镜确诊。
- 慢性氯胺酮毒性的管理重点在于戒断,其效应通常可逆。
适用人群与场景
- 娱乐性使用氯胺酮后出现急性不良反应的人群。
- 长期使用氯胺酮出现慢性毒性效应(膀胱炎、胆管病)的人群。
诊断标准与关键阈值
- 急性氯胺酮中毒的诊断通常基于患者病史、临床特征(如呕吐、流涎或喉痉挛)以及神经精神症状。
- 慢性氯胺酮毒性导致的胆管病可通过内镜逆行胰胆管造影确诊。
- 慢性氯胺酮毒性导致的膀胱炎可通过膀胱镜确诊。
处置流程与药物剂量
- 急性临床毒性的治疗以支持治疗为主,并对特定不良反应进行经验性处理。
- 苯二氮䓬类药物推荐作为初始治疗,以减少激越、过度神经肌肉活动和血压。
- 膀胱炎的管理是多学科、多层次的,遵循药物治疗和手术的阶梯式方法。
- 胆管病的管理可能需要疼痛管理,必要时进行胆道支架置入以缓解梗阻。
- 慢性氯胺酮毒性的管理重点在于戒断,其效应通常可逆。
红旗征与不能漏的情况
- 呕吐、流涎或喉痉挛。
- 神经精神症状。
研究设计与关键结果
- 检索OVID MEDLINE(1950年1月至2023年4月)和Web of Science(1900年至2023年4月),获得5,268条非重复引文,最终纳入185篇相关文献(病例报告、病例系列、药代动力学研究、药理学相关动物研究和综述)。
- 氯胺酮主要作为谷氨酸N-甲基-D-天冬氨酸受体的非竞争性拮抗剂,导致与临床氯胺酮分离麻醉相关的反应性丧失。
- 氯胺酮在人体内的半衰期为1.5至5小时。
- 娱乐性使用后的急性不良反应多样,可包括意识受损、头晕、行为异常、幻觉、腹痛和呕吐。
- 慢性使用可导致言语信息处理受损、膀胱炎和胆管病。
证据类型、等级与局限
- 证据类型:综述,纳入185篇文献(病例报告、病例系列、药代动力学研究、药理学相关动物研究和综述)。
- 局限:原文未报告局限性
对床旁实践的改变
- 急性氯胺酮中毒的处理以支持治疗为主,苯二氮䓬类药物推荐作为初始治疗以减少激越、过度神经肌肉活动和血压。
- 慢性氯胺酮毒性(膀胱炎、胆管病)的管理重点在于戒断,其效应通常可逆。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Ketamine is a pharmaceutical drug possessing both analgesic and anaesthetic properties. As an anaesthetic, it induces anaesthesia by producing analgesia with a state of altered consciousness while maintaining airway tone, respiratory drive, and hemodynamic stability. At lower doses, it has psychoactive properties and has gained popularity as a recreational drug.
OBJECTIVES: To review the epidemiology, mechanisms of toxicity, pharmacokinetics, clinical features, diagnosis and management of ketamine toxicity.
METHODS: Both OVID MEDLINE (January 1950-April 2023) and Web of Science (1900-April 2023) databases were searched using the term "ketamine" in combination with the keywords "pharmacokinetics", "kinetics", "poisoning", "poison", "toxicity", "ingestion", "adverse effects", "overdose", and "intoxication". Furthermore, bibliographies of identified articles were screened for additional relevant studies. These searches produced 5,268 non-duplicate citations; 185 articles (case reports, case series, pharmacokinetic studies, animal studies pertinent to pharmacology, and reviews) were considered relevant. Those excluded were other animal investigations, therapeutic human clinical investigations, commentaries, editorials, cases with no clinical relevance and post-mortem investigations.
EPIDEMIOLOGY: Following its introduction into medical practice in the early 1970s, ketamine has become a popular recreational drug. Its use has become associated with the dance culture, electronic and dubstep dance events.
MECHANISM OF ACTION: Ketamine acts primarily as a non-competitive antagonist on the glutamate N-methyl-D-aspartate receptor, causing the loss of responsiveness that is associated with clinical ketamine dissociative anaesthesia.
PHARMACOKINETICS: Absorption of ketamine is rapid though the rate of uptake and bioavailability is determined by the route of exposure. Ketamine is metabolized extensively in the liver. Initially, both isomers are metabolized to their major active metabolite, norketamine, by CYP2B6, CYP3A4 and CYP2C9 isoforms. The hydroxylation of the cyclohexan-1-one ring of norketamine to the three positional isomers of hydroxynorketamine occurs by CYP2B6 and CYP2A6. The dehydronorketamine metabolite occurs either by direct dehydrogenation from norketamine via CYP2B6 metabolism or non-enzymatic dehydration of hydroxynorketamine. Norketamine, the dehydronorketamine isomers, and hydroxynorketamine have pharmacological activity. The elimination of ketamine is primarily by the kidneys, though unchanged ketamine accounts for only a small percentage in the urine. The half-life of ketamine in humans is between 1.5 and 5 h.
CLINICAL FEATURES: Acute adverse effects following recreational use are diverse and can include impaired consciousness, dizziness, irrational behaviour, hallucinations, abdominal pain and vomiting. Chronic use can result in impaired verbal information processing, cystitis and cholangiopathy.
DIAGNOSIS: The diagnosis of acute ketamine intoxication is typically made on the basis of the patient's history, clinical features, such as vomiting, sialorrhea, or laryngospasm, along with neuropsychiatric features. Chronic effects of ketamine toxicity can result in cholangiopathy and cystitis, which can be confirmed by endoscopic retrograde cholangiopancreatography and cystoscopy, respectively.
MANAGEMENT: Treatment of acute clinical toxicity is predominantly supportive with empiric management of specific adverse effects. Benzodiazepines are recommended as initial treatment to reduce agitation, excess neuromuscular activity and blood pressure. Management of cystitis is multidisciplinary and multi-tiered, following a stepwise approach of pharmacotherapy and surgery. Management of cholangiopathy may require pain management and, where necessary, biliary stenting to alleviate obstructions. Chronic effects of ketamine toxicity are typically reversible, with management focusing on abstinence.
CONCLUSIONS: Ketamine is a dissociative drug employed predominantly in emergency medicine; it has also become popular as a recreational drug. Its recreational use can result in acute neuropsychiatric effects, whereas chronic use can result in cystitis and cholangiopathy.
参考来源
- Schep LJ, Slaughter RJ, Watts M, et al. The clinical toxicology of ketamine. Clin Toxicol (Phila). 2023. PMID: 37267048. doi:10.1080/15563650.2023.2212125
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。